JP2011528332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528332A5 JP2011528332A5 JP2011517954A JP2011517954A JP2011528332A5 JP 2011528332 A5 JP2011528332 A5 JP 2011528332A5 JP 2011517954 A JP2011517954 A JP 2011517954A JP 2011517954 A JP2011517954 A JP 2011517954A JP 2011528332 A5 JP2011528332 A5 JP 2011528332A5
- Authority
- JP
- Japan
- Prior art keywords
- human beta
- beta defensin
- composition
- seq
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 8
- 108060002187 Def1 Proteins 0.000 claims 4
- 230000037396 body weight Effects 0.000 claims 4
- 108091005293 human DEFB4A protein Proteins 0.000 claims 3
- 102000028366 human DEFB4A protein Human genes 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000004624 dermatitis Diseases 0.000 claims 2
- 231100000406 dermatitis Toxicity 0.000 claims 2
- 200000000018 inflammatory disease Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 208000002205 Allergic Conjunctivitis Diseases 0.000 claims 1
- 206010002556 Ankylosing spondylitis Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 208000006673 Asthma Diseases 0.000 claims 1
- 206010004161 Basedow's disease Diseases 0.000 claims 1
- 208000009137 Behcet Syndrome Diseases 0.000 claims 1
- 201000008335 Behcet's disease Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 101000233317 DEFB1 Proteins 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 201000004779 Graves' disease Diseases 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 206010025135 Lupus erythematosus Diseases 0.000 claims 1
- 206010028417 Myasthenia gravis Diseases 0.000 claims 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 Rhinitis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010040767 Sjogren's syndrome Diseases 0.000 claims 1
- 210000003491 Skin Anatomy 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000001154 acute Effects 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000000172 allergic Effects 0.000 claims 1
- 201000004384 alopecia Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 102000038635 human DEFB1 protein Human genes 0.000 claims 1
- 108091003827 human DEFB103A protein Proteins 0.000 claims 1
- 102000037916 human DEFB103A protein Human genes 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 201000001263 psoriatic arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000009594 systemic scleroderma Diseases 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
Claims (8)
- 関節リウマチ、骨関節炎、多発性硬化症、アテローム性動脈硬化症、強皮症(全身性硬化症)、ループス、全身性エリテマトーデス(SLE)、(急性)糸球体腎炎、喘息、慢性閉塞性肺疾患(COPD)、呼吸窮迫症候群(ARDS)、血管炎、ブドウ膜炎、皮膚炎、アトピー性皮膚炎、脱毛症、(アレルギー性)鼻炎、アレルギー性結膜炎、重症筋無力症、硬化性皮膚炎、サルコイドーシス、乾癬性関節炎、乾癬、強直性脊椎炎、若年性特発性関節炎、グレーブス病、シェーグレン症候群、及びベーチェット病から成る群から選択される炎症性疾患又は障害の処置のための医薬組成物であって、配列番号1、配列番号2、配列番号3、又は配列番号4のアミノ酸配列に対して少なくとも80%の同一性を有する、ヒト・ベータ・デフェンシンを含む、前記組成物。
- 非経口投与される、請求項1に記載の組成物。
- 皮下、又は静脈内に投与される、請求項2に記載の組成物。
- 前記ヒト・ベータ・デフェンシンが、約0.001mg/kg体重〜約10mg/kg体重、好ましくは約0.01mg/kg体重〜約10mg/kg体重の1日投与量にて投与される、請求項1〜3のいずれか1項に記載の組成物。
- 前記ヒト・ベータ・デフェンシンが、ヒト・ベータ・デフェンシン1、ヒト・ベータ・デフェンシン2、ヒト・ベータ・デフェンシン3、又はヒト・ベータ・デフェンシン4である、請求項1〜4のいずれか1項に記載の組成物。
- 前記ヒト・ベータ・デフェンシンが、配列番号2のアミノ酸配列に対して少なくとも80%の同一性を有する、請求項1〜5のいずれか1項に記載の組成物。
- 前記ヒト・ベータ・デフェンシンが、ヒト・ベータ・デフェンシン2である、請求項1〜6のいずれか1項に記載の組成物。
- TNF‐アルファ活性が、処置した組織において低下する、請求項1〜7のいずれか1項に記載の組成物。
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08160761 | 2008-07-18 | ||
EP08160761.6 | 2008-07-18 | ||
EP08162486 | 2008-08-15 | ||
EP08162486.8 | 2008-08-15 | ||
EP08163614 | 2008-09-03 | ||
EP08163614.4 | 2008-09-03 | ||
EP09160448.8 | 2009-05-15 | ||
EP09160448 | 2009-05-15 | ||
PCT/EP2009/059251 WO2010007165A2 (en) | 2008-07-18 | 2009-07-17 | Treatment of inflammatory diseases with mammal beta defensins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011528332A JP2011528332A (ja) | 2011-11-17 |
JP2011528332A5 true JP2011528332A5 (ja) | 2012-04-12 |
Family
ID=41445843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011517954A Pending JP2011528332A (ja) | 2008-07-18 | 2009-07-17 | 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置 |
Country Status (18)
Country | Link |
---|---|
US (1) | US20100016232A1 (ja) |
EP (1) | EP2320929B1 (ja) |
JP (1) | JP2011528332A (ja) |
KR (2) | KR20110044863A (ja) |
CN (1) | CN102159232A (ja) |
AP (1) | AP2011005537A0 (ja) |
AR (1) | AR072524A1 (ja) |
AU (1) | AU2009272680A1 (ja) |
BR (1) | BRPI0915780A2 (ja) |
CA (1) | CA2730674A1 (ja) |
CL (1) | CL2011000098A1 (ja) |
EA (1) | EA201170218A1 (ja) |
IL (1) | IL210714A0 (ja) |
MX (1) | MX2011000569A (ja) |
NZ (1) | NZ590466A (ja) |
TW (1) | TW201004641A (ja) |
WO (1) | WO2010007165A2 (ja) |
ZA (1) | ZA201100462B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR072525A1 (es) * | 2008-07-18 | 2010-09-01 | Novozymes As | Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo. |
EP2320930A2 (en) | 2008-07-18 | 2011-05-18 | Novozymes Adenium Biotech A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
US8858964B2 (en) | 2010-04-15 | 2014-10-14 | Marine Polymer Technologies, Inc. | Anti-bacterial applications of poly-N-acetylglucosamine nanofibers |
KR101320472B1 (ko) * | 2010-06-16 | 2013-10-23 | 주식회사 나이벡 | 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물 |
CA2832859C (en) * | 2011-04-15 | 2020-06-16 | Marine Polymer Technologies, Inc. | Treatment of disease with poly-n-acetylglucosamine nanofibers |
JP6219277B2 (ja) | 2011-07-08 | 2017-10-25 | ディフェンシン セラピューティクス アンパルトセルスカブDefensin Therapeutics Aps | 炎症性腸疾患の経口治療 |
WO2013026794A1 (en) | 2011-08-19 | 2013-02-28 | Novozymes | Novel immunomodulatory peptide |
JP6151981B2 (ja) * | 2013-06-18 | 2017-06-21 | 一般社団法人健康科学リソースセンター | 関節リウマチ患者における生物学的製剤の有効性の予測方法 |
US11111284B2 (en) | 2014-08-21 | 2021-09-07 | The General Hospital Corporation | Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing |
GB201603653D0 (en) * | 2016-03-02 | 2016-04-13 | Cambridge Entpr Ltd | Combination Therapy |
MX2019006848A (es) | 2016-12-13 | 2019-10-07 | Defensin Therapeutics Aps | Metodos para tratar condiciones inflamatorias de los pulmones. |
KR102631543B1 (ko) * | 2018-03-14 | 2024-02-01 | 서울대학교산학협력단 | 세포 투과능 및 근육 재생능을 가지는 이중 기능성 펩타이드 및 이의 용도 |
KR102631542B1 (ko) * | 2018-03-14 | 2024-02-01 | 서울대학교산학협력단 | 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도 |
WO2020046002A1 (ko) * | 2018-08-31 | 2020-03-05 | 주식회사 나이벡 | 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도 |
WO2023144701A1 (en) | 2022-01-28 | 2023-08-03 | Johnson & Johnson Consumer Inc. | Biomarkers predictive of atopic dermatitis |
WO2023194839A1 (en) | 2022-04-04 | 2023-10-12 | Donnelly | Window of opportunity skin treatment regimen and composition for preventing the onset of or treating atopic dermatitis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7338936B2 (en) * | 2000-11-28 | 2008-03-04 | House Ear Institute | Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis |
US20080194481A1 (en) * | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
JP2006514106A (ja) * | 2002-12-19 | 2006-04-27 | ヒルマン,イチャク | 抗菌ペプチド阻害剤による疾患治療 |
GB0514482D0 (en) * | 2005-07-14 | 2005-08-17 | Ares Trading Sa | Protein |
WO2007081486A2 (en) * | 2005-12-15 | 2007-07-19 | Ventria Bioscience | Oral administration of defensins to treat intestinal diseases |
KR20100061486A (ko) * | 2007-09-11 | 2010-06-07 | 몬도바이오테크 래보래토리즈 아게 | 치료제로서의 펩티드의 용도 |
AR072525A1 (es) * | 2008-07-18 | 2010-09-01 | Novozymes As | Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo. |
EP2320930A2 (en) * | 2008-07-18 | 2011-05-18 | Novozymes Adenium Biotech A/S | Treatment of inflammatory bowel diseases with mammal beta defensins |
-
2009
- 2009-07-17 JP JP2011517954A patent/JP2011528332A/ja active Pending
- 2009-07-17 US US12/504,930 patent/US20100016232A1/en not_active Abandoned
- 2009-07-17 MX MX2011000569A patent/MX2011000569A/es not_active Application Discontinuation
- 2009-07-17 EA EA201170218A patent/EA201170218A1/ru unknown
- 2009-07-17 NZ NZ590466A patent/NZ590466A/xx not_active IP Right Cessation
- 2009-07-17 AU AU2009272680A patent/AU2009272680A1/en not_active Abandoned
- 2009-07-17 CA CA2730674A patent/CA2730674A1/en not_active Abandoned
- 2009-07-17 AR ARP090102740A patent/AR072524A1/es not_active Application Discontinuation
- 2009-07-17 KR KR1020117002950A patent/KR20110044863A/ko not_active Application Discontinuation
- 2009-07-17 CN CN2009801363423A patent/CN102159232A/zh active Pending
- 2009-07-17 AP AP2011005537A patent/AP2011005537A0/xx unknown
- 2009-07-17 EP EP09780789.5A patent/EP2320929B1/en active Active
- 2009-07-17 KR KR1020117002473A patent/KR20110031962A/ko not_active Application Discontinuation
- 2009-07-17 BR BRPI0915780-8A patent/BRPI0915780A2/pt not_active IP Right Cessation
- 2009-07-17 WO PCT/EP2009/059251 patent/WO2010007165A2/en active Application Filing
- 2009-07-20 TW TW098124404A patent/TW201004641A/zh unknown
-
2011
- 2011-01-17 CL CL2011000098A patent/CL2011000098A1/es unknown
- 2011-01-18 IL IL210714A patent/IL210714A0/en unknown
- 2011-01-18 ZA ZA2011/00462A patent/ZA201100462B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2011528332A5 (ja) | ||
JP2014506321A5 (ja) | ||
NZ590466A (en) | Treatment of inflammatory diseases with mammal beta defensins | |
JP2014527040A5 (ja) | ||
JP2015517489A5 (ja) | ||
HRP20171176T1 (hr) | C5ar antagonisti | |
JP2011528333A5 (ja) | ||
JP2010505418A5 (ja) | ||
JP2015145426A5 (ja) | ||
JP2013529647A5 (ja) | ||
JP2012518420A5 (ja) | ||
EP2824111A3 (en) | Anti-C5A Antibodies and Methods for Using the Antibodies | |
JP2009526756A5 (ja) | ||
JP2011225596A5 (ja) | ||
HRP20220250T1 (hr) | Modificirani nukleozidi, nukleotidi i nukleinske kiseline, te njihove uporabe | |
JP2011506330A5 (ja) | ||
MX2010001400A (es) | Metodo para tratar enfermedades mediadas cxcr3 usando piperazinas heterociclicas sustituidas. | |
JP2012509687A5 (ja) | ||
JP2010273685A5 (ja) | ||
JP2008541759A5 (ja) | ||
JP2009501202A5 (ja) | ||
JP2014510082A5 (ja) | ||
JP2011528334A5 (ja) | ||
JP2010515682A5 (ja) | ||
JP2016540749A5 (ja) |